Efficacy and safety of Ginkgo Biloba for cognitive function and fatigue in breast cancer patients after primary adjuvant treatment

niversity of Sydney0 个研究点目标入组 72 人开始时间: 2010年2月5日最近更新: 2020年9月14日

适应症

试验速览

暂无简介。

•Diagnosis of invasive breast cancer for which definitive surgery was performed.
•Patient has completed chemotherapy and/or radiotherapy and/or targeted therapy for adjuvant treatment (if received) for breast cancer at least six months previously. Patients who did not require chemotherapy are eligible but must be at least six months post surgery and radiotherapy.
•Patient has completed at least 2 months of anti-cancer hormonal treatment (if received).
•Patient is less than two years post completing primary adjuvant treatment.
•Self report cognitive symptoms based on a Single Item Question assessing their subjective change in cognitive function since their cancer diagnosis. Participants must select one of three possible responses (yes, no, unknown) to the question: Do you think your brain is working as well as it was before your cancer diagnosis?” To meet eligibility, participants must choose the NO” response.
•Speak fluent English and read to at least year 8 standard;
•Written informed consent;
•Accessible for treatment and follow-up

•Eastern Cooperative Oncology Group (ECOG) performance status < or = 2;
•Any evidence of extra-nodal metastatic disease;
•Any major pre-existing psychiatric history or dementia, alcohol abuse, current use of psychotropic medication that might lead to cognitive problems other than benzodiazepines for nausea or sleep or selective serotonin reuptake inhibitor (SSRI) for hot flashes;
•Pre-existing neurological condition or any other co-morbidity which may interfere with their ability to perform cognitive testing;
•Previous chemotherapy for a malignancy.
•Life expectancy < 2years;
•use of Ginkgo biloba within 4 weeks of randomisation;
•Any contraindication to taking ginkgo biloba.

发起方